Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018

Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018

Summary

GlobalDatas clinical trial report, Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018" provides an overview of Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Proliferative Diabetic Retinopathy (NPDR). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Non-Proliferative Diabetic Retinopathy (NPDR) 29
Mar 20, 2018: Aflibercept shows promising data for nonproliferative DR 29
Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial 29
Feb 09, 2018: Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy 29
Clinical Trial Profile Snapshots 31
Appendix 67
Abbreviations 67
Definitions 67
Research Methodology 68
Secondary Research 68
About GlobalData 69
Contact Us 69
Source 69

List Of Tables

List of Tables
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region, 2018* 7
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 10
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 11
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries, 2018* 12
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 13
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 14
Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2018* 15
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2018* 18
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase, 2018* 20
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 21
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 22
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 23
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 24
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 25
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 26
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 27
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 28

List Of Figures

List of Figures
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 9
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 10
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 11
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 12
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 13
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 14
Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2018* 15
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 16
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 17
Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2018* 18
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 19
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 20
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 21
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 22
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 23
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 24
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 25
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 26
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 27
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 28
GlobalData Methodology 68

Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018

Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018 provides an overview of Non-Proliferative Diabetic Retinopathy

USD 2500 View Report

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2018

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2018, provides an overview of the

USD 2000 View Report

Proliferative Diabetic Retinopathy (PDR) Global Clinical Trials Review, H1, 2018

Proliferative Diabetic Retinopathy (PDR) Global Clinical Trials Review, H1, 2018The clinical trial report, Proliferative Diabetic Retinopathy (PDR) Global Clinical Trials Review, H1, 2018 provides an overview of Proliferative Diabetic Retinopathy

USD 2500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available